SEOUL, Nov. 18 (Korea Bizwire) — Celltrion Inc., a leading pharmaceutical firm in South Korea, said Wednesday that it will build a third plant in the country in response to rising manufacturing demand. The 500 billion-won (US$452 million) plant in the country’s biotech hub of Songdo, west of Seoul, will have a bioreactor capacity of [...]
SEOUL, Nov. 11 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc.’s COVID-19 treatment kills the coronavirus within 4-5 days, effectively protecting patients with mild symptoms from developing a severe case, the company’s chief said Wednesday. Celltrion Group Chairman Seo Jung-jin said the first stage trial of CT-P59, anti-COVID-19 monoclonal antibody treatment, shortened the recovery [...]
SEOUL, Nov. 9 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Monday that its net profit jumped 185.4 percent on-year in the third quarter on the back of robust sales of its products in overseas markets. Net profit came to 175.8 billion won (US$157.8 million) during the July-Sept. period on a [...]
SEOUL, Nov. 2 (Korea Bizwire) — South Korean biopharmaceutical giant Celltrion Inc. said Monday it has signed an agreement worth 210 billion won (US$185 million) to supply a diagnostic kit for the novel coronavirus in the United States. Under the agreement, Celltrion’s rapid antigen kit, Sampinute, will be distributed by Prime Healthcare Distributors in the [...]
SEOUL, Aug. 26 (Korea Bizwire) — Celltrion Inc., a leading pharmaceutical firm in South Korea, said Wednesday that it will conduct an additional phase one clinical trial of its coronavirus treatment on patients. Celltrion’s CT-P59 will be administered to nine COVID-19 patients with mild symptoms to evaluate the safety and efficacy of the antiviral antibody [...]
SEOUL, Aug. 12 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Wednesday that its two kinds of diagnostic kits for the novel coronavirus began sales in the United States. A point-of-care antigen testing (POCT) kit, dubbed “Sampinute,” co-developed by local health care firm BBB, was commercialized following emergency approval by the U.S. Food [...]
SEOUL, Aug. 7 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday that its net profit jumped 77 percent on-year in the second quarter on the back of robust sales of its blockbuster biosimilar, Truxima. Net profit came to 138.6 billion won (US$117 million) during the April-June period on a consolidated [...]
SEOUL, July 20 (Korea Bizwire) — Celltrion, a leading pharmaceutical firm in South Korea, said Monday that it is preparing to start commercial production of its antibody treatment for the new coronavirus as early as September. Celltrion plans to begin the production of its antiviral antibody treatment for the COVID-19 virus at its plant in [...]
SEOUL, July 17 (Korea Bizwire) — South Korea approved phase one clinical trials for Celltrion Inc.’s coronavirus antibody treatment substance, the country’s drug safety agency said Friday. The move to test CT-P59 marks the first time that a locally made genetic recombination antibody treatment material has been given the green light to be used on [...]
SEOUL, July 9 (Korea Bizwire) — The chief of the pharmaceutical group Celltrion saw the value of his stock holdings rise the most among the heads of South Korea’s major business groups in the first half, data showed Thursday. Seo Jung-jin held 5.85 trillion won (US$4.9 billion) worth of listed shares in group flagship Celltrion [...]